LEXARIA BIOSCIENCE CORP. Cost, Amortization
LEXARIA BIOSCIENCE CORP. (LEXX) reported Cost, Amortization of $1.12 thousand for the 6-month period ending 2022-02-28, per its 10-Q filed 2022-04-11.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsAndServicesSoldAmortization · last filed 2022-04-11
- LEXARIA BIOSCIENCE CORP. cost, amortization for the quarter ending 2021-08-31 was $1.60K, a 2.83% increase year-over-year.
- LEXARIA BIOSCIENCE CORP. cost, amortization for the quarter ending 2021-05-31 was $3.31K.
- LEXARIA BIOSCIENCE CORP. cost, amortization for the quarter ending 2021-02-28 was $1.22K.
- LEXARIA BIOSCIENCE CORP. cost, amortization for the quarter ending 2020-11-30 was $4.79K.
- LEXARIA BIOSCIENCE CORP. cost, amortization for fiscal 2021 was $10.93K, a 466.70% increase from fiscal 2020.
- LEXARIA BIOSCIENCE CORP. cost, amortization for fiscal 2020 was $1.93K.
| Period end | Cost, Amortization 3 month | Cost, Amortization 6 month | Cost, Amortization 9 month | Cost, Amortization 12 month |
|---|---|---|---|---|
| 2022-02-28 | $1.12K 10-Q · filed 2022-04-11 | |||
| 2021-08-31 | $1.60K derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-29 | $4.92K derived: sum of 2 quarters · filed 2021-11-29 | $6.14K derived: sum of 3 quarters · filed 2022-04-11 | $10.93K 10-K · filed 2021-11-29 |
| 2021-05-31 | $3.31K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-07-15 | $4.54K derived: sum of 2 quarters · filed 2022-04-11 | $9.32K 10-Q · filed 2021-07-15 | $10.88K derived: sum of 4 quarters · filed 2022-04-11 |
| 2021-02-28 | $1.22K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-04-11 | $6.01K 10-Q · filed 2022-04-11 | $7.57K derived: sum of 3 quarters · filed 2022-04-11 | |
| 2020-11-30 | $4.79K 10-Q · filed 2021-01-14 | $6.35K derived: sum of 2 quarters · filed 2021-11-29 | ||
| 2020-08-31 | $1.56K derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-29 | $1.93K 10-K · filed 2021-11-29 | ||
| 2020-05-31 | $371.00 10-Q · filed 2020-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |